Publication | Closed Access

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Breast OncologyHealth SciencesMedicineClinical TrialsImmune Checkpoint InhibitorBreast CancerPharmacotherapyTrastuzumab-based Adjuvant TherapyCancer TreatmentOncologyRadiation OncologyHer2-positive Breast Cancer